WEST LAFAYETTE, IN--(Marketwire - May 11, 2011) - BASi (Bioanalytical Systems Inc.) (NASDAQ: BASI), a leader in drug discovery and development services and research instrumentation, announced it has hired a new Director of Laboratory Operations at its facility in Kenilworth, Warwickshire, England. In addition, a new Senior Scientist/Principal Investigator has joined the bioanalysis team.
Peter White is the new Director of Laboratory Operations. He joins BASi after working for more than 10 years in the pharmaceutical industry, most recently as a senior research scientist at AstraZeneca. Peter is an experienced mass spectrometrist with a strong background in bioanalysis, drug metabolism and pharmacokinetics. "Peter has extensive bioanalytical knowledge and experience gained across many DMPK functions which, combined with his leadership capability, will strengthen our breadth and depth of analytical expertise," said General Manager John Maltas. "Whilst his primary role will be to manage all aspects of the laboratory operations, he will also be a key contact for clients."
White has a BSc (Hons) in Applied Biochemical Sciences from the University of Ulster. His work has been published in scientific media, including the Journal of Chronic Obstructive Pulmonary Disease.
Bhavna Mistry joins BASi as a Senior Scientist/Principal Investigator. She has several years experience using and applying analytical methodologies in the pharmaceutical industry. Bhavna's most recent experience includes study management as a PI/SD in a regulatory bioanalytical environment at AstraZeneca and this experience will enhance further BASi's reputation for responsiveness and effective communication to clients.
Bhavna has a BSc (Hons) in Forensic & Analytical Science from Sheffield Hallam University. She recently presented a poster at the Analytical Research Forum at Loughborough University.
BASi is a drug discovery and development services company providing contract research services and research instruments and supplies to the world's leading pharmaceutical companies and medical research organizations. The company focuses on developing innovative services and products that increase efficiency and reduce the cost of taking new and generic drugs to market. Visit www.BASInc.com.
This release contains forward-looking statements that are subject to risks and
uncertainties including, but not limited to, risks and uncertainties related to changes
in the market and demand for our products and services, the development,
marketing and sales of products and services, changes in technology, industry
standards and regulatory standards, and various market and operating risks detailed
in the company's filings with the Securities and Exchange Commission.